In Vivo Antitumor Activity of Two New Seven-substituted Water-soluble Camptothecin Analogues

Cancer Research

Volumn 55, Issue 3, 1995, Pages 603-609

  Emerson, David L ^a   Besterman, Jeffrey M ^a   Brown, H Hoger ^a   Evans, Michael G ^a   Leitner, Peter P ^a   Luzzio, Michael J ^a   Shaffer, Joel E ^a   Sternbach, Daniel D ^a   Ueliling, David ^a   Vuong, Alain ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

10,11 ETHYLENEDIOXY 7 (4 METHYLPIPERAZINOMETHYLENE)CAMPTOTHECIN; 10,11 METHYLENEDIOXY 7 (4 METHYLPIPERAZINOMETHYLENE)CAMPTOTHECIN; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CAMPTOTHECIN DERIVATIVE; CYTOTOXIN; DNA TOPOISOMERASE; GI 149893; GLYCOPROTEIN P; GYRASE INHIBITOR; IRINOTECAN; LURTOTECAN; TOPOTECAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; COLON TUMOR; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SOLUBILITY; FEMALE; HUMAN; HUMAN CELL; MELANOMA CELL; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMAL; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CAMPTOTHECIN; CATTLE; CELL DIVISION; CELL LINE; CELL SURVIVAL; COLONIC NEOPLASMS; COMPARATIVE STUDY; DNA TOPOISOMERASES, TYPE I; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMAN; MICE; MICE, NUDE; THYMUS GLAND; TOPOTECAN; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0028911408     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Liu, L. F. DNA topoisomerase poisons as anti-tumor drugs. Annu. Rev. Biochem., 58: 351–375, 1989.
2. Giovanella, B. C., Stehlin, J. S., Wall, M. E., Wani, M. C., Nicholas, A. W., Liu, L. F., Silber, R., and Potmesil, M. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science (Washington, DC), 246: 1046–1048, 1989.
3. Kawato, Y., Furuta, T., Aonuma, M., Yasuoka, M., Yokokura, T., and Matsumoto, K. Anti-tumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice. Cancer Chemother. Pharmacol., 28: 192–198, 1991.
4. Houghton, P. J., Cheshire, P. J., Myers, L., Stewart, C. F., Synold, T. W., and Houghton, J. A. Evaluation of 9-dimethyaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors. Cancer Chemother. Pharmacol., 31: 229–239, 1992.
5. Rowinsky, E. K., Grochow, L. B., Hendricks, C. B., Ettinger, D. S., Forastiere, A. A., Hurowitz, L. A., McGuire, W. P., Sartorius, S. E., Lubejko, B. G., Kaufmann, S. H., and Donhower, R. C. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J. Clin. Oncol., 10: 647–656, 1992.
6. Negoro, S., Fukuoka, M., Masuda, N., Takada, M., Kusunoki, Y., Matusi, K., Takifuji, N., Kudoh, S., Niitani, H., and Taguchi, T. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J. Natl. Cancer Inst., 83: 1164–1168, 1991.
7. Fukuoka, M., Niitani, H., Suzuki, A., Motomiya, M., Hasegawa, K., Nishiwaki, Y., Kuriyama, T., Airyoshi, Y., Negoro, S., Masuda, N., Nakajima, S., and Taguchi, T. A phase II study of CPT-II, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J. Clin. Oncol., 10: 16–20, 1992.
8. Gottlieb, J. A., Guarino, A. M., Call, J. B., Oliverio, V. T., and Block, J. B. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother. Rep., 54: 461–470, 1970.
9. Muggia, F. M., Creaven, P. J., Hansen, H. H., Cohen, M. H., and Selawry, O. S. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother. Rep., 56: 515–521, 1972.
10. Jaxel, C., Kohn, K. W., Wani, M. C., and Pommier, Y. Structure-activity study of the actions of camptothecin derivatives on mammalian I: evidence for a specific receptor site and a relation to anti-tumor activity. Cancer Res., 49: 1465–1469, 1989.
11. Strausfeld, U., and Richter, A. Simultaneous purification of DNA topoisomerase I and II from eukaryotic cells. Prep. Biochem., 19: 37–48, 1989.
12. Halligan, B. D., Edwards, K. A., and Liu, L. Purification of a type II DNA topoisomerase from bovine calf thymus. J. Biol. Chem., 260: 2475–2482, 1985.
13. Bradley, G., Naik, M., and Ling, V. P-glycoprotein expression in multidrug-resistant human ovarian carcinoma cell lines. Cancer Res., 49: 2790–2796, 1989.
14. Luzzio, M. J., Besterman, J. M., Evans, M. G., Lackey, K. E., Leitner, P., Peel, M. R., Sisco, J. M., Sternbach, D. D., Tong, T., and Uehling, D. E. Novel water-soluble camptothecin analogs as inhibitors of topoisomerase I. Proc. Am. Assoc. Cancer Res., 34: 332, 1993.
15. Kang, M. C., Bankston, D. D., Erickson, G. A., Fang, F. G., Lackey, J. W., Lewis, G. S., Lichty, M. E., Lowery, M. W., Mader, C., McDougald, D. L., Mook, R. A., Partridge, J., and Xie, S. Total synthesis of the novel water soluble camptothecin analog GI147211C, a potent topoisomerase I inhibitor. Proc. Am. Cancer Res., 34: 332, 1993.
16. Wani, M. C., Nicholas, A. W., and Wall, M. E. Plant antitumor agents. 28. Resolution of a key tricyclic synthon, 5′(R5)-l,5-dioxo-5′-hydroxy-2′H5′H,6′H-6′-oxy-pyrano[3′,4′N]A6,8-tetrahydroindolizine: total synthesis and antitumor activity of 20(5)- and 20(R)-camptothecin. J. Med. Chem., 30: 2317–2319, 1987.
17. Wani, M. C., Campbell, H. F., Brine, G. A., Kepler, J. A., Wall, M. E., and Levine, S. G. Plant antitumor agents. DC. Total synthesis of {H-camptothecin. J. Am. Chem. Soc., 94: 3631–3632, 1972.
18. Tewey, K. M., Chen, G. L., Nelson, E. M., and Liu, L. F. Interactive anti-tumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J. Biol. Chem, 259: 9182–9187, 1984.
19. Hsaing, Y. H., Hertzberg, R, Hect, S., and Liu, L. F. Camptothecin induced protein-linked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem., 260: 14873–14878, 1985.
20. Liu, L. F., Rowe, T. C., Yang, L., Tewey, K. M., and Chen, G. L. Cleavage of DNA by mammalian DNA topoisomerase II. J. Biol. Chem., 258: 15365–15370, 1983.
21. Plumb, J. A., Milroy, R., and Kaye, S. B. Effects of the pH dependence of 3-(4,5-dimethyl-2-yl)-2,5-diphenyl-tetrazolium bromide-formazan adsorption on che-mosensitivity determined by a novel tetrazolium-based assay. Cancer Res., 49: 4435–4440, 1989.
22. Hendricks, C. B., Rowinsky, E. K., Grochow, L. B., Donehower, R. C., and Kaufmann, S. H. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res., 52: 2268–2278, 1992.
23. Gupta, R. S., Gupta, R., Eng, B., Lock, R. B., Ross, W. E., Hertzberg, R. P., Caranfa, M. J., and Johnson, R. K. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res., 48: 6404–6410, 1988.
24. Eckardt, J. R., Burns, H. A., Rothenberg, M. L., VonHoff, D. D., and Kuhn, J. G. Topoisomerase I inhibitors: promising novel compounds. Contemp. Oncol.: 47–60, 1993.
25. Pantazis, P., Hinz, H. R., Mendoza, J. T., Kozielski, A. J., Williams, L. J., Stehlin, J. S. Jr., and Giovanella, B. C. Complete inhibition of growth followed by death of human malignant melanoma cells in vitro and regression of human melanoma xenografts in immunodeficient mice induced by camptothecins. Cancer Res., 52: 3980–3987, 1992.
26. Emerson, D. L., McLntyre, G, Luzzio, M. J., and Wissel, P. S. Pre-clinical anti-tumor activity of a novel water-soluble camptothecin analog (GI147211C). Ann. Oncol., 5(Suppl. 5): 185, 1994.
27. Wall, M. E., Wani, M. C., Nicholas, A. W., Manikumar, G., Tele, C., Moore, L., Truesdale, A, Leitner, P. P., and Besterman, J. M. Plant antitumor agents. 30. Synthesis and structure activity of novel camptothecin analogs. J. Med. Chem., 36: 2689–2700, 1993.
28. Wani, M. C., Nicholas, A. W., and Wall, M. E. Plant antitumor agents. 23. Synthesis and antileukemic activity of camptothecin analogs. J. Med. Chem., 29: 2358–2363, 1986.
29. Wall, M. E., and Wani, M. C. In: M. Potmesil and K. K. Kohn, eds. DNA Topoisomerases in Cancer, pp. 93–102. New York: Oxford University Press, 1991.
30. Wall, M. E., Wani, M., Cook, C. E., Palmer, K. H., McPhail, A. T., and Sim, G. A. Plant antitumor agents. 1. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc., 88: 3888–3890, 1966.
31. Venditti, J. M., and Abbott, B. J. Studies on oncologic agents from natural sources. Correlations of activity against tumors and clinical effectiveness. Lloydia, 30: 332, 1967.
32. Dewys, W. D., Humphreys, S. R., and Goldin, A. Studies on therapeutic effectiveness of drugs with tumor weight and survival time indices of Walker 256 carcinoma. Cancer Chemother. Rep., 52: 229, 1968.
33. Sawada, S., Okajima, S., Aiyama, R., Nokata, K., Furuta, T., Yokokura, T., Sugino, E., Yamaguchi, K., and Miyasaka, T. Synthesis and anti-tumor activity of 20(5)-camptothecin dérivates: carbamate-linked, water-soluble derivatives of 7-ethyl-10-hydroxycamptothecin. Chem. Pharm. Bull., 39: 1446–1454, 1991.